Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

• DOI: 10.1200/jco.1998.16.2.593
• Publication Date: 2017-02-24T10:08:03Z
• Authors: J R Berenson; A Lichtenstein; L Porter; M A Dimopoulos; R Bordoni; S George; A Lipton; A Keller; O Ballester; M Kovacs; H Blacklock; R Bell; J F Simeone; D J Reitsma; M Heffernan; J Seaman; R D Knight
• Keywords: Pathologic fracture

PURPOSE To determine the efficacy and safety of 21 monthly cycles pamidronate therapy in patients with advanced multiple myeloma. PATIENTS AND METHODS Patients stage III myeloma at least one lytic lesion received either placebo or 90 mg intravenously administered as a 4-hour infusion for cycles. At study entry, were stratified according to whether they receive first-line (stratum 1) second-line 2) antimyeloma chemotherapy. Skeletal events (pathologic fracture, radiation surgery bone, spinal cord compression) hypercalcemia assessed monthly. RESULTS The results first nine previously reported are extended Of 392 randomized patients, could be evaluated 198 who 179 placebo. After cycles, proportion developed any skeletal event was lower pamidronate-group (P = .015). mean number per year less (1.3) than placebo-treated (2.2; P .008). Although survival not different between pamidronate-treated group overall, stratum 2 lived longer those (14 v months, .041). Pamidronate safe well tolerated during therapy. CONCLUSION Long-term infusions an adjunct chemotherapy superior alone reducing may improve on salvage